Coeptis Therapeutics
Manufacturing · Pennsylvania, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
105 Bradford Rd Ste 420, Wexford, Pennsy...Phone Number
(724) 934-6467Website
www.coeptistx.comRevenue
<$5 MillionStock Symbol
COEPIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Coeptis Therapeutics
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical company. It is developing cell therapy platforms for cancer, autoimmune, and infectious diseases that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Its product portfolio and rights are licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, natural killer cell therapy technology. The company is also developing a multi-antigen CAR T technology licensed from the University of Pittsburgh, and the GEAR cell therapy and companion diagnostic platforms, which are developing with VyGen-Bio and medical researchers at the Karolinska Institute. Its Product Pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administeredRead more
Coeptis Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Coeptis Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Coeptis Therapeutics launches new products
Earning: See what the market has to say on Coeptis Therapeutics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Coeptis Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Coeptis Therapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Check if Coeptis Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if Coeptis Therapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Coeptis Therapeutics
Funding: Get notified immidiatlly once Coeptis Therapeutics has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Coeptis Therapeutics
Compare insights from companies similar to Coeptis Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Coeptis Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Coeptis Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Coeptis Therapeutics.
Coeptis Therapeutics financials insights
Gather financial insights about Coeptis Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Debt
$77K
2024
Series A
$4.3M
Coeptis Therapeutics Tech Stack
A closer look at the technologies used by Coeptis Therapeutics
Most Recent Scoops
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Partnership
Partnership, Facilities Relocation/Expansion, Research & Development, Product Management, Artificial Intelligence, Blockchain, Cryptocurrency, Marketing Strategy
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Event
Person-Based
Events, Search, Medical Research
Partnership
Project
Partnership, Intellectual Property, Medical Research, Contracts
Coeptis Therapeutics News & Media
Coeptis Announces Approval of Z Squared Inc.’s Nasdaq Listing Application
~ Approval Marks Satisfaction of Key Closing Condition in Pending Merger ~Coeptis Receives Shareholder Approval Towards Z Squared Merger
Shareholder Approval Clears a Key Condition to Close Shareholder Approval Clears a Key Condition to CloseCoeptis Therapeutics S-4 Declared Effective by SEC, Proxy Mailing Begins in Anticipation of the Merger Transaction with Z Squared
~ Annual/Special Meeting of Shareholders to be Held on January 30, 2026 ~ ~ Annual/Special Meeting of Shareholders to be Held on January 30, 2026 ~Vanderbilt Report: Coeptis Shows How Biotech Can Fund Itself While Innovating
Coeptis Therapeutics (NASDAQ: COEP) is pioneering a dual-track model designed to sustain innovation while reducing reliance on dilutive funding.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Coeptis Therapeutics
Sign Up For FreeTo access detailed company insights
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical company. It is developing cell therapy platforms for cancer, autoimmune, and infectious diseases that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Its product portfolio and rights are licensed from Dev... Read More
